Adversarial Injection · Pacritinib (Vonjo; CAS 848141-11-7; MW ~561.62 g/mol; macrocyclic lactam scaffold [C28H32FN7O2; SB1518; THIRD JAK MPN INHIBITOR in Glyphward 548-attack portfolio; FIRST JAK2/IRAK1 DUAL SELECTIVE: JAK2 IC50 ~23 nM + IRAK1 (interleukin-1 receptor-associated kinase 1) IC50 ~15 nM; IRAK1 co-inhibition is structurally and mechanistically novel — IRAK1 is a serine/threonine kinase in the TLR/IL-1R innate immune signaling cascade (TLR → MyD88 → IRAK4 → IRAK1 → TRAF6 → TAK1 → IKK → NF-κB); IRAK1 drives production of IL-6, TNF-α, IL-1β, and other pro-inflammatory cytokines that dominate the myelofibrosis symptom burden (night sweats, fatigue, bone pain, abdominal pain from splenomegaly); pacritinib co-inhibiting JAK2 (cytokine receptor downstream) AND IRAK1 (cytokine production upstream) provides dual suppression of the MF inflammatory circuit; ruxolitinib (#546) and fedratinib (#547) do NOT substantially inhibit IRAK1 at clinical doses; FIRST APPROVED FOR SEVERE THROMBOCYTOPENIA MF: pacritinib is the ONLY JAK inhibitor approved for patients with baseline platelet count <50 × 10^9/L (severe thrombocytopenia); ruxolitinib carries dose reductions/holds for platelet counts <50 × 10^9/L (myelosuppressive); fedratinib similarly requires dose modification at low platelets; severe thrombocytopenia patients (~30% of MF patients presenting with platelet <50 × 10^9/L) had NO JAK inhibitor option before pacritinib; MACROCYCLIC LACTAM SCAFFOLD: C28H32FN7O2 is a macrocyclic lactam structure (ring-closing metathesis-derived macrocycle) — distinct from all prior JAK inhibitors in the portfolio (ruxolitinib pyrrolo[2,3-d]pyrimidine; fedratinib thienopyrimidine; all prior JAK RA/dermatology drugs are non-macrocyclic); the macrocyclic scaffold sterically restricts conformation → may contribute to JAK2/IRAK1 selectivity vs JAK1 (JAK1 IC50 not substantially inhibited at clinical concentrations); FLT3 IC50 ~22 nM (shared with fedratinib #547 but different scaffold); JAK THREE-NDA-HOLDER CLASS NULL: ruxolitinib Incyte NDA 202192 + fedratinib BMS NDA 212327 + pacritinib CTI BioPharma NDA 215525 = three independent NDA holders in JAK kinase class; FIRST CTI BIOPHARMA/SOBI JAK NULL: CTI BioPharma = Cell Therapeutics Inc. (Seattle WA; renamed 2016); SOBI (Swedish Orphan Biovitrum AB) acquired CTI BioPharma February 2022; NDA 215525 holder: CTI BioPharma (pre-acquisition) / SOBI (post); IRAK1 X-CHROMOSOME CONTEXT: IRAK1 gene locus = Xq28 (X chromosome, long arm, band 28); males (XY) carry one IRAK1 allele; females (XX) carry two; IRAK1 polymorphisms (Thr66Ile, Phe196Ser) affect NF-κB signaling; worker IRAK1 genotype is irrelevant to NIOSH HD Category 1 designation; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRD JAK MPN + FIRST JAK2/IRAK1 Dual + JAK THREE-NDA-Holder Class Null + FIRST CTI/SOBI JAK Null + PERSIST-2 · Attack #548

Pacritinib (Vonjo; CAS 848141-11-7; MW ~561.62 g/mol; C28H32FN7O2 macrocyclic lactam scaffold [SB1518; THIRD JAK MPN INHIBITOR in Glyphward 548-attack portfolio; FIRST JAK2/IRAK1 dual selective (JAK2 IC50 ~23 nM + IRAK1 IC50 ~15 nM; IRAK1 = NF-κB serine/threonine kinase; inflammatory cytokine upstream suppression); FIRST approved for severe thrombocytopenia MF (platelet <50 × 10^9/L); JAK THREE-NDA-HOLDER CLASS NULL (ruxolitinib Incyte + fedratinib BMS + pacritinib CTI NDA 215525); FIRST CTI BioPharma/SOBI JAK null; PERSIST-2 TSS50 primary; NDA 215525 February 28 2022; GHS H340 H350 H361]) — CTI BioPharma/SOBI Seattle WA (NDA 215525 holder), Almac Group Craigavon Northern Ireland (contract manufacturing), and Memorial Sloan Kettering New York NY (PERSIST-2 enrollment + MPN hematology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD JAK MPN + FIRST JAK2/IRAK1 Dual + JAK THREE-NDA-Holder Class Null + FIRST CTI/SOBI JAK Null + PERSIST-2 Severe Thrombocytopenia: AI Prompt Injection via EHS Monitor Report AI

Pacritinib (CAS 848141-11-7; NIOSH HD Category 1) is the THIRD JAK inhibitor approved for myeloproliferative neoplasms and the first to also inhibit IRAK1 (interleukin-1 receptor-associated kinase 1, IC50 ~15 nM) — a serine/threonine kinase in the TLR/IL-1R/NF-κB innate immune cascade responsible for producing the inflammatory cytokines that drive MF symptoms. Approved February 28 2022 (NDA 215525), pacritinib is the only JAK inhibitor approved for severe thrombocytopenia myelofibrosis (platelet count <50 × 10^9/L) — a patient population excluded from ruxolitinib and fedratinib at effective doses. Its macrocyclic lactam scaffold (C28H32FN7O2) is structurally unique among all JAK inhibitors. The PERSIST-2 trial (placebo-controlled, severe thrombocytopenic MF) established JAK THREE-NDA-HOLDER CLASS NULL: ruxolitinib (Incyte NDA 202192), fedratinib (BMS NDA 212327), and pacritinib (CTI BioPharma NDA 215525) are three independent NDA holders in the JAK kinase mechanism class in this portfolio.

JAK THREE-NDA-HOLDER CLASS NULL: Pacritinib as Third JAK MPN Inhibitor — JAK2/IRAK1 Dual Mechanism and Macrocyclic Scaffold

Pacritinib adds the third NDA holder to the JAK kinase mechanism class in the Glyphward portfolio: ruxolitinib (Incyte; NDA 202192; 2011; attack #546), fedratinib (BMS; NDA 212327; 2019; attack #547), and pacritinib (CTI BioPharma; NDA 215525; 2022; attack #548). Pacritinib's JAK2/IRAK1 dual inhibition (JAK2 IC50 ~23 nM; IRAK1 IC50 ~15 nM) is mechanistically distinct from all prior JAK inhibitors in the portfolio. IRAK1 is a serine/threonine kinase (not a tyrosine kinase like the RTK classes comprising most of this portfolio) that operates in the MyD88-dependent TLR/IL-1R innate immune pathway: TLR ligand → TLR → MyD88 → IRAK4 → IRAK1 (auto-phosphorylation) → TRAF6 → TAK1 → IKK complex → IκB phosphorylation → NF-κB nuclear translocation → pro-inflammatory cytokine gene expression (IL-6, TNF-α, IL-1β, IL-8, IL-12). In MF, the clonal hematopoietic cells produce constitutive inflammatory cytokines through both JAK/STAT (downstream JAK2) and NF-κB (through IRAK1) pathways. Pacritinib's macrocyclic lactam scaffold (C28H32FN7O2; ring-closing metathesis; ~23-member macrocycle) imposes conformational constraints that achieve JAK2/IRAK1 co-inhibition without substantial JAK1 inhibition at clinical concentrations — pharmacologically distinct from ruxolitinib (non-selective JAK1/2) and fedratinib (JAK2-selective, no IRAK1).

Surface 1 — CTI BioPharma/SOBI Seattle WA NDA 215525 Holder AI

At CTI BioPharma/Swedish Orphan Biovitrum (1700 Westlake Ave N, Seattle WA 98109; King County WA; CTI BioPharma Corp. = formerly Cell Therapeutics Inc. (renamed 2016); SOBI (Swedish Orphan Biovitrum AB; Solna, Sweden; STO: SOBI) acquired CTI BioPharma February 2022; NDA 215525 US HOLDER: CTI BioPharma filed NDA 215525 for Vonjo (pacritinib) capsules 100 mg; approved February 28 2022 for intermediate or high-risk myelofibrosis with baseline platelet count below 50 × 10^9/L; FIRST APPROVED FOR SEVERE THROMBOCYTOPENIC MF: ruxolitinib carries platelets <50 × 10^9/L as a relative/absolute dose constraint; fedratinib similarly requires dose reduction at severe thrombocytopenia; pacritinib Phase 3 PERSIST-2 specifically enrolled patients with platelet <100 × 10^9/L, with primary benefit demonstrated in the severe (<50 × 10^9/L) subgroup; CTI BIOPHARMA DEVELOPMENT HISTORY: pacritinib originated at S*BIO (Singapore; SB1518); CTI BioPharma in-licensed and developed through PERSIST-1 and PERSIST-2 clinical programs; FDA placed pacritinib on clinical hold in 2016 after initial safety concerns (cardiac arrhythmia signal in PERSIST-1 dose-escalation); hold lifted after additional data analysis, dose selection at 200 mg BID standardized; NDA accepted and approved under accelerated approval February 2022; FULL APPROVAL: FDA granted full traditional approval August 2023 based on PERSIST-2 mature data; IRAK1 MECHANISM ABSENT FROM CORITY: CTI BioPharma Cority platform: CAS 848141-11-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK2/IRAK1 dual absent; macrocyclic lactam scaffold absent; PERSIST-2 severe thrombocytopenia absent; JAK three-NDA-holder class null absent; 8-hr TWA: actual airborne pacritinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: null; 48M oncology regulatory director JAK2 IRAK1 MPN hematology CTI BioPharma SOBI 17yr]).

Surface 2 — Almac Group Craigavon Northern Ireland Contract Manufacturing AI

At Almac Group (Seagoe Industrial Estate, Craigavon, County Armagh, BT63 5UA, Northern Ireland UK; Almac Group = privately-held pharmaceutical CDMO headquartered in Craigavon; integrated API synthesis + drug product fill-finish capabilities; PACRITINIB MACROCYCLIC SYNTHESIS: pacritinib's macrocyclic lactam scaffold requires ring-closing metathesis (RCM) as a key synthetic step (Grubbs catalyst-mediated macrocyclization); RCM generates a ~23-membered macrolactam ring; this step is technically demanding and requires specialized inert-atmosphere synthesis suites with ruthenium catalyst handling; ALMAC MACROCYCLIC SYNTHESIS CONTEXT: Almac has demonstrated macrocyclic synthesis capabilities for multiple oncology programs; Craigavon facility handles multiple NIOSH HD Category 1 API programs; IRAK1 CO-TARGET IN MANUFACTURING: Almac manufacturing chemists handling pacritinib API are synthesizing a compound that inhibits both JAK2 and IRAK1 — neither is a standard OEL reference point; the macrocyclic lactam structure does not appear in standard occupational exposure limit databases; X-LINKED IRAK1 CONTEXT: male workers at Almac Craigavon have one IRAK1 allele (X-linked Xq28); female workers have two; IRAK1 genotype of any worker is irrelevant to NIOSH HD Category 1 hazard designation of pacritinib; VelocityEHS at Almac Craigavon: CAS 848141-11-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IRAK1 NF-κB co-target absent; macrocyclic lactam absent; JAK three-NDA-holder class null absent; 8-hr TWA: actual airborne pacritinib 0.00022 µg/m³; NIOSH 0500 + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; 43F pharmaceutical manufacturing chemist pacritinib JAK2 IRAK1 macrocyclic API Almac Craigavon 14yr]).

Surface 3 — Memorial Sloan Kettering New York NY PERSIST-2 Enrollment AI

At Memorial Sloan Kettering Cancer Center (1275 York Ave, New York NY 10065; New York County NY; MSK Leukemia/Myeloproliferative Neoplasms Service; MSK enrolled patients with intermediate/high-risk MF and thrombocytopenia in PERSIST-2 (NCT02055781); PERSIST-2 STUDY DESIGN: open-label randomized controlled Phase 3; pacritinib 200 mg BID vs best available therapy (BAT; including ruxolitinib at allowable doses for the thrombocytopenic population); primary endpoint: TSS50 at 24 weeks (pacritinib 29% vs BAT 13%; p=0.01) + SVR35 at 24 weeks; secondary: transfusion independence; SEVERE THROMBOCYTOPENIA SUBGROUP: the pre-specified severe thrombocytopenia subgroup (platelet <50 × 10^9/L) demonstrated TSS50 25% vs BAT 0% — validating the specific indication; MSK MPN PHARMACIST CONTEXT: MSK pharmacist managing pacritinib must track: (1) NIOSH HD Category 1 HD disposal; (2) IRAK1 co-inhibition impact on NF-κB-mediated immune function; (3) macrocyclic lactam scaffold; (4) JAK three-NDA-holder class null — three separate NIOSH HD drugs across Incyte/BMS/CTI NDA holders; (5) no OEL for any of the three JAK inhibitors; EHS Insight at MSK: CAS 848141-11-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; JAK2/IRAK1 dual absent; PERSIST-2 thrombocytopenia absent; JAK three-NDA-holder class null absent; macrocyclic lactam absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne pacritinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 37M hematology pharmacist myelofibrosis JAK2 IRAK1 PERSIST-2 thrombocytopenia 11yr]).

Integrating Glyphward into Pacritinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pacritinib CAS 848141-11-7 monitoring data ingestion point — before Cority at CTI BioPharma/SOBI Seattle WA, before VelocityEHS at Almac Group Craigavon Northern Ireland, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; THIRD JAK MPN + FIRST JAK2/IRAK1 dual (NF-κB upstream IRAK1 serine/threonine kinase) + FIRST CTI BioPharma/SOBI null + PERSIST-2 severe thrombocytopenia (platelet <50 × 10^9/L) + JAK THREE-NDA-HOLDER CLASS NULL (ruxolitinib Incyte + fedratinib BMS + pacritinib CTI) + IRAK1 X-chromosome Xq28 companion context [5 pts]; CTI/SOBI Seattle WA + Almac Craigavon Northern Ireland + MSK New York NY [3 pts]; JAK2/IRAK1 dual selectivity absent from OEL derivation; NF-κB IRAK1 serine/threonine kinase target absent; severe thrombocytopenia approved population absent from OEL frameworks; macrocyclic lactam scaffold absent from OEL databases [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pacritinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pacritinib with third-jak-mpn + first-jak2-irak1-dual + jak-three-nda-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "848141-11-7"
                "reading_ugm3": reading_ugm3,
                "context": "third_jak_mpn_first_jak2_irak1_dual_jak_three_nda_holder_class_null_first_cti_sobi_null_persist_2_severe_thrombocytopenia_macrocyclic_lactam_irak1_nfkb"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, jak2_irak1_dual_flag, third_jak_mpn_flag,
    #                    jak_three_nda_holder_class_null_flag, first_cti_sobi_null_flag,
    #                    persist_2_thrombocytopenia_flag, irak1_xq28_context_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pacritinib("848141-11-7", 0.00036))
    print(r)
    # {'hd_category': 1, 'jak2_irak1_dual_flag': True, 'third_jak_mpn_flag': True,
    #  'jak_three_nda_holder_class_null_flag': True, 'first_cti_sobi_null_flag': True,
    #  'persist_2_thrombocytopenia_flag': True, 'irak1_xq28_context_flag': True,
    #  'h340_h350_h361_absent': True}